middle.news
Why Afamelanotide Alone Fails to Repigment Vitiligo Skin: CLINUVEL Study Reveals
9:44am on Wednesday 18th of June, 2025 AEST
•
Pharmaceuticals
Read Story
Why Afamelanotide Alone Fails to Repigment Vitiligo Skin: CLINUVEL Study Reveals
9:44am on Wednesday 18th of June, 2025 AEST
Key Points
Afamelanotide monotherapy ineffective for vitiligo repigmentation
Adjunct narrowband UVB phototherapy essential for activating pigment cells
CUV104 pilot study enrolled three patients with darker skin types
Ongoing Phase III trials focus on combined afamelanotide and NB-UVB treatment
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Clinuvel Pharmaceuticals (ASX:CUV)
OPEN ARTICLE